Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | FSHR | P23945 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6886778 | 0.89 | CTSK (0.35) | CTSKCTSLMEN1MAPK1KMT2A | |
| SCHEMBL571503 | 0.85 | CTSK (0.38) | CTSKCTSLMEN1MAPK1KMT2A | |
| SCHEMBL76972 | 0.79 | CTSK (0.36) | CTSKCTSLMEN1MAPK1KMT2A | |
| SCHEMBL571320 | 0.79 | CTSK (0.36) | CTSKCTSLMEN1MAPK1KMT2A | |
| SCHEMBL8284389 | 0.78 | CTSK (0.36) | CTSKCTSLMEN1MAPK1KMT2A | |
| SCHEMBL21119394 | 0.77 | CTSK (0.33) | CTSKCTSLMEN1MAPK1KMT2A | |
| SCHEMBL22363136 | 0.75 | — | — | |
| SCHEMBL6886785 | 0.75 | MEN1 (0.40) | CTSKMEN1MAPK1KMT2AAPLNR | |
| SCHEMBL7925145 | 0.75 | MEN1 (0.40) | CTSKMEN1MAPK1KMT2AAPLNR | |
| SCHEMBL21505983 | 0.75 | MEN1 (0.37) | CTSKCTSLMEN1MAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200268730-A1 | AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200268730-A1 | AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES | HDGF, FABP1, NR1H4 | CTSK 2291/4885CTSL 1754/4885MEN1 4681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.